Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

83.94EUR
11:36am EDT
Change (% chg)

€0.47 (+0.56%)
Prev Close
€83.47
Open
€83.90
Day's High
€84.00
Day's Low
€83.12
Volume
1,733,029
Avg. Vol
2,509,945
52-wk High
€84.00
52-wk Low
€62.50

Latest Key Developments (Source: Significant Developments)

U.S. list price for Sanofi, Regeneron's Dupixent $37,000
11:47am EDT 

Sanofi : Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: [SASY.PA] (Reporting by Ben Hirschler) ((uk.online@reuters.com;)).  Full Article

U.S. FDA says approves new eczema drug Dupixent
11:47am EDT 

U.S. FDA: FDA approves new eczema drug Dupixent . FDA granted the application for Dupixent priority review and breakthrough therapy designation .FDA granted the approval of Dupixent to Regeneron Pharmaceuticals Inc.  Full Article

Regeneron and Sanofi announce FDA approval of Dupixent
11:40am EDT 

Sanofi SA : Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis . Dupixent is expected to be available to patients and providers in U.S. later this week .Regeneron and Sanofi Genzyme, specialty care global business unit of Sanofi, will market Dupixent in United States.  Full Article

Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi
Monday, 27 Mar 2017 08:30am EDT 

Vivus Inc : Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi . Says Sanofi will provide transition services to avoid adverse impacts to regulatory approval applications in process .Agreement with Sanofi to return commercial rights for Stendra in Africa, Middle East, Turkey, Commonwealth Of Independent States, including Russia, to Co.  Full Article

Sanofi and Voluntis announce a global alliance to deliver digital insulin titration solutions for people with type 2 diabetes
Tuesday, 14 Mar 2017 05:46am EDT 

Sanofi Sa : Sanofi and Voluntis announce a global alliance to deliver digital insulin titration solutions for people with type 2 diabetes .Voluntis - Sanofi and Voluntis will launch pilot programs using mobile phone application in North America and several European countries.  Full Article

UK regulator gives positive opinion on Sanofi/Regeneron's dupilumab product
Tuesday, 14 Mar 2017 04:30am EDT 

Sanofi : Sanofi says UK's Medicines & Healthcare Products Regulatory Agency (MHRA) has granted dupilumab, a product which treats for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). . The decision means that eligible adults with severe atopic dermatitis can access dupilumab before the drug is granted marketing authorisation in the UK, Sanofi adds in statement .Dupilumab is currently under joint development with Regeneron and Sanofi and its safety and efficacy have not been fully evaluated by any regulatory body. The formal EU regulatory application for dupilumab is currently under review by the European Medicines Agency (EMA)..  Full Article

Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions
Tuesday, 7 Mar 2017 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions .Regeneron Pharmaceuticals Inc says effect of praluent on cardiovascular (CV) morbidity and mortality has not yet been determined.  Full Article

Sanofi Pasteur and Medimmune collaborate on monoclonal antibody to prevent illnesses associated with RSV
Friday, 3 Mar 2017 02:00am EST 

Sanofi : Sanofi Pasteur and Medimmune [MEDI.UL] collaborate on monoclonal antibody to prevent illnesses associated with RSV . Sanofi Pasteur will make an upfront payment of 120 million euros and pay up to 495 million euros upon achievement of certain development and sales-related milestones . Two companies will share all costs and profits equally . Medimmune will continue to lead all development activity up to first approval, and AstraZeneca will retain medi8897 manufacturing activities .Sanofi Pasteur will lead commercialization activities for medi8897.  Full Article

Sanofi Genzyme says kevzara now available in Canada for treatment of adult patients with moderately to severely active rheumatoid arthritis
Tuesday, 28 Feb 2017 08:00am EST 

Sanofi SA :Sanofi Genzyme - kevzara now available in Canada for treatment of adult patients with moderately to severely active rheumatoid arthritis.  Full Article

FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi
Friday, 24 Feb 2017 01:47pm EST 

U.S. Federal Trade Commission (FTC) :U.S. FTC - Approved final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Sanofi would likely be anticompetitive.  Full Article

More From Around the Web

UPDATE 3-FDA approves Regeneron, Sanofi $37,000 per year eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.